Sotrovimab

Generic Name
Sotrovimab
Brand Names
Xevudy
Drug Type
Biotech
Chemical Formula
-
CAS Number
2423014-07-5
Unique Ingredient Identifier
1MTK0BPN8V
Background

Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalizatio...

Indication

In Europe, sotrovimab is indicated for the treatment of COVID-19 in patients ≥12 years old and weighing ≥40kg who do not require supplemental oxygen and are at high risk of progressing to severe disease.

Associated Conditions
Coronavirus Disease 2019 (COVID‑19)
Associated Therapies
-

Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain

Conditions
Interventions
First Posted Date
2022-06-01
Last Posted Date
2022-06-01
Lead Sponsor
Abu Dhabi Health Services Company
Target Recruit Count
20000
Registration Number
NCT05398718
Locations
🇧🇭

The National Taskforce for combating COVID-19, Royal Medical Services., Manama, Bahrain

Non-inferiority Trial on Treatments in Early COVID-19

First Posted Date
2022-04-11
Last Posted Date
2023-11-07
Lead Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Target Recruit Count
536
Registration Number
NCT05321394
Locations
🇮🇹

Azienda Ospedaliera Cannizzaro, Catania, Italy

🇮🇹

Azienda Ospedaliera dei Colli, presidio ospedaliero Cotugno, Napoli, Italy

🇮🇹

Azienda Ospedaliera S. Maria della Misericordia, Perugia, Italy

and more 16 locations

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19

Phase 4
Completed
Conditions
Interventions
First Posted Date
2022-03-31
Last Posted Date
2024-10-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
217
Registration Number
NCT05305651
Locations
🇬🇧

GSK Investigational Site, Plymouth, United Kingdom

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-03-15
Last Posted Date
2022-11-08
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
504
Registration Number
NCT05280717
Locations
🇺🇸

Investigative Site, West Jordan, Utah, United States

COVID-19 and Disease Progression to the Severe Form: A Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

Conditions
First Posted Date
2022-03-07
Last Posted Date
2022-03-07
Lead Sponsor
University of Milano Bicocca
Target Recruit Count
1000
Registration Number
NCT05268601
Locations
🇮🇹

Asst-Monza Ospedale San Gerardo, Monza, Lombardia, Italy

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-01-27
Last Posted Date
2024-08-15
Lead Sponsor
Sophia Koo, M.D.
Target Recruit Count
93
Registration Number
NCT05210101
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Non-inferiority Trial on Monoclonal Antibodies in COVID-19

First Posted Date
2022-01-25
Last Posted Date
2022-07-26
Lead Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Target Recruit Count
319
Registration Number
NCT05205759
Locations
🇮🇹

AOU Città della Salute e Scienza, Presidio Molinette, Torino, Italy

🇮🇹

PO Garibaldi Nesima, Catania, Italy

🇮🇹

Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy

and more 17 locations

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

First Posted Date
2022-01-18
Last Posted Date
2023-11-22
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
1000
Registration Number
NCT05195060
Locations
🇳🇱

Amsterdam University Medical Centre, Amsterdam, Noord-Holland, Netherlands

🇳🇱

Amsterdam University Medical centre - VUMC, Amsterdam, Noord Holland, Netherlands

🇳🇱

Leiden universitair medisch centrum, Leiden, Netherlands

and more 1 locations

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

First Posted Date
2021-09-13
Last Posted Date
2024-10-28
Lead Sponsor
University of Oxford
Target Recruit Count
3800
Registration Number
NCT05041907
Locations
🇳🇵

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

🇧🇷

Universidade Federal de Minas Gerais, Minas Gerais, Brazil

🇱🇦

Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

First Posted Date
2021-05-03
Last Posted Date
2024-03-22
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
5000
Registration Number
NCT04870333
Locations
🇬🇧

Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust, King's Lynn, United Kingdom

🇬🇧

University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

🇬🇧

Imperial College Healthcare NHS Trust, London, United Kingdom

and more 42 locations
© Copyright 2024. All Rights Reserved by MedPath